RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
Engineered immune cells target lymphoma after transplant in early trial
Disease control OngoingThis early-phase study tests a new type of immunotherapy for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial treatment. Participants first receive a stem cell transplant, then get an infusion of their own immune cells that have been genetically …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New hope for Tough-to-Treat lymphoma: targeted drug shows promise
Disease control OngoingThis study tests a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shrink or disappe…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New hope for relapsed lymphoma: drug cocktail targets cancer cells
Disease control OngoingThis early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC